SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Sanderling Venture Partners VI LP

(Last)

(First)

(Middle)

1300 S. EL CAMINO REAL SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/23/2024		P⁽¹⁾		243,356	A	$3.702	946,744	D
Common Stock	01/23/2024		P⁽¹⁾		144,676	A	$3.702	727,433	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock	01/23/2024		P⁽¹⁾		194,472	A	$3.702	435,148	I	By Sanderling Ventures VII, L.P.
Common Stock	01/23/2024		P⁽¹⁾		51,032	A	$3.702	114,260	I	By Sanderling Ventures VII (Canada), L.P.
Common Stock	01/23/2024		P⁽¹⁾		13,184	A	$3.702	27,609	I	By Sanderling Ventures VII Annex Fund, L.P.
Common Stock	01/23/2024		P⁽¹⁾		3,920	A	$3.702	21,602	I	By Sanderling Ventures Management VI
Common Stock	01/23/2024		P⁽¹⁾		28,744	A	$3.702	30,292	I	By Sanderling Ventures Management VII

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrant	$5.36	01/23/2024		P⁽¹⁾		121,678		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	121,678	$0.125	121,678	D
Warrant	$7.15	01/23/2024		P⁽¹⁾		121,678		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	121,678	$0.125	121,678	D
Warrant	$5.36	01/23/2024		P⁽¹⁾		72,338		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	72,338	$0.125	72,338	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Warrant	$7.15	01/23/2024		P⁽¹⁾		72,338		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	72,338	$0.125	72,338	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Warrant	$5.36	01/23/2024		P⁽¹⁾		97,236		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	97,236	$0.125	97,236	I	By Sanderling Ventures VII, L.P.
Warrant	$7.15	01/23/2024		P⁽¹⁾		97,236		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	97,236	$0.125	97,236	I	By Sanderling Ventures VII, L.P.
Warrant	$5.36	01/23/2024		P⁽¹⁾		25,516		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	25,516	$0.125	25,516	I	By Sanderling Ventures VII (Canada), L.P.
Warrant	$7.15	01/23/2024		P⁽¹⁾		25,516		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	25,516	$0.125	25,516	I	By Sanderling Ventures VII (Canada), L.P.
Warrant	$5.36	01/23/2024		P⁽¹⁾		6,592		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	6,592	$0.125	6,592	I	By Sanderling Ventures VII Annex Fund, L.P.
Warrant	$7.15	01/23/2024		P⁽¹⁾		6,592		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	6,592	$0.125	6,592	I	By Sanderling Ventures VII Annex Fund, L.P.
Warrant	$5.36	01/23/2024		P⁽¹⁾		1,960		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	1,960	$0.125	1,960	I	By Sanderling Ventures Management VI
Warrant	$7.15	01/23/2024		P⁽¹⁾		1,960		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	1,960	$0.125	1,960	I	By Sanderling Ventures Management VI
Warrant	$5.36	01/23/2024		P⁽¹⁾		14,372		01/23/2024⁽²⁾	12/31/2024⁽²⁾	Common Stock	14,372	$0.125	14,372	I	By Sanderling Ventures Management VII
Warrant	$7.15	01/23/2024		P⁽¹⁾		14,372		01/23/2024⁽³⁾	12/31/2026⁽³⁾	Common Stock	14,372	$0.125	14,372	I	By Sanderling Ventures Management VII

1. Name and Address of Reporting Person^*

Sanderling Venture Partners VI LP

(Last)

(First)

(Middle)

1300 S. EL CAMINO REAL SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Sanderling Venture Partners VI Co Investment Fund LP

(Last)

(First)

(Middle)

1300 S EL CAMINO REAL

SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Sanderling Ventures Management VI

(Last)

(First)

(Middle)

1300 S EL CAMINO REAL

SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Sanderling Ventures VII, L.P.

(Last)

(First)

(Middle)

1300 S. EL CAMINO REAL

SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Sanderling Ventures VII Annex Fund, L.P.

(Last)

(First)

(Middle)

1300 S EL CAMINO REAL

SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Sanderling Ventures VII (Canada), L.P.

(Last)

(First)

(Middle)

1300 S. EL CAMINO REAL SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Sanderling Ventures Management VII

(Last)

(First)

(Middle)

1300 S. EL CAMINO REAL SUITE 203

(Street)

SAN MATEO

94402

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.

2. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.

3. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

	/s/ Sanderling Venture Partners VI, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, L.P., its General Partner	01/25/2024
	/s/ Sanderling Venture Partners VI Co-Investment Fund, L.P., By: /s/ Timothy C. Mills, Managing Director of Middleton, McNeil & Mills Associates VI, LLC, its General Partner	01/25/2024
	/s/ Sanderling Ventures VII (Canada), L.P., By: /s/ D. Michael Dixon, President of Sanderling Ventures VII (Canada) GP Inc., General Partner of Sanderling Ventures VII (Canada) G.P., L.P, its General Partner	01/25/2024
	/s/ Sanderling Ventures VII, L.P. , By: /s/ Timothy C. Mills, Managing Director of M4 Partners VII, LLC, its General Partner	01/25/2024
	/s/ Sanderling Ventures VII Annex Fund, L.P., By: /s/ Timothy C. Mills, Managing Director of M4 Partners VII Annex, LLC, its General Partner	01/25/2024
	/s/ Sanderling Ventures Management VII, By: /s/ Timothy C. Mills, Owner	01/25/2024
	/s/ Sanderling Ventures Management VI, By: /s/ Timothy C. Mills, Owner	01/25/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.